-+ 0.00%
-+ 0.00%
-+ 0.00%

China Biopharmaceutical announced that the world's first CDK2/4/6 inhibitor coumoxil capsules independently developed by its subsidiary, Zhengda Tianqing, have been officially approved for marketing for HR+/HER2-locally advanced or metastatic breast cancer for previous endocrine treatment.

Zhitongcaijing·12/11/2025 10:33:04
Listen to the news
China Biopharmaceutical announced that the world's first CDK2/4/6 inhibitor coumoxil capsules independently developed by its subsidiary, Zhengda Tianqing, have been officially approved for marketing for HR+/HER2-locally advanced or metastatic breast cancer for previous endocrine treatment.